Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,555 | 92 | 1,441 |
| Samples | 157 | 20 | 135 |
| Peptides | 148 | 17 | 133 |
Function
PCBP2 · Poly(rC) binding protein 2
The protein encoded by this gene appears to be multifunctional. Along with PCBP-1 and hnRNPK, it is one of the major cellular poly(rC)-binding proteins. The encoded protein contains three K-homologous (KH) domains which may be involved in RNA binding. Together with PCBP-1, this protein also functions as a translational coactivator of poliovirus RNA via a sequence-specific interaction with stem-loop IV of the IRES, promoting poliovirus RNA replication by binding to its 5'-terminal cloverleaf structure. It has also been implicated in translational control of the 15-lipoxygenase mRNA, human papillomavirus type 16 L2 mRNA, and hepatitis A virus RNA. The encoded protein is also suggested to play a part in formation of a sequence-specific alpha-globin mRNP complex which is associated with alpha-globin mRNA stability. This multiexon structural mRNA is thought to be retrotransposed to generate PCBP-1, an intronless gene with functions similar to that of PCBP2. This gene and PCBP-1 have paralogous genes (PCBP3 and PCBP4) which are thought to have arisen as a result of duplication events of entire genes. This gene also has two processed pseudogenes (PCBP2P1 and PCBP2P2). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2018].
Isoforms & Proteins
11 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000546463 | Q15366-3 | 161 | 113 |
| ENST00000359462 | Q15366-2 | 150 | 110 |
| ENST00000439930 | Q15366 | 149 | 109 |
| ENST00000552296 | Q15366-6 | 148 | 108 |
| ENST00000447282 | Q15366-5 | 138 | 100 |
| ENST00000548933 | Q15366-5 | 138 | 100 |
| ENST00000359282 | Q15366-4 | 137 | 99 |
| ENST00000549863 | F8VZX2* | 137 | 99 |
| ENST00000552819 | Q15366-8 | 133 | 96 |
| ENST00000437231 | Q15366-7 | 132 | 95 |
| ENST00000455667 | Q15366-7 | 132 | 95 |
Gene Properties
Recurrent Mutations
All 113 amino-acid changes on canonical ENST00000546463 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PCBP2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PCBP2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Endometrial Carcinoma | 2/42 5% | 10/612 2% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Melanoma | 1/210 0% | 15/1899 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Colorectal Carcinoma | 3/143 2% | 21/3239 1% |
| Other Solid Cancers | 0/94 0% | 10/1515 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 10/1592 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Gastric Carcinoma | 1/74 1% | 8/1809 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 3/810 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 5/1390 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Breast Carcinoma | 2/144 1% | 7/3264 0% |
| Pancreatic Carcinoma | 1/89 1% | 3/1611 0% |
| Glioma | 0/52 0% | 5/2127 0% |
| Hepatocellular Carcinoma | 0/46 0% | 5/2210 0% |
| Kidney Carcinoma | 0/85 0% | 4/1862 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 2/2550 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Ovarian Carcinoma | 0/109 0% | 1/998 0% |
| Prostate Carcinoma | 0/13 0% | 2/2105 0% |
Mutation Distribution
Where PCBP2 is mutated · all tissues, split by cell line vs tissue
How many mutations in PCBP2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,555 mutations in PCBP2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|